---
document_datetime: 2024-10-16 11:52:46
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vypeti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vypeti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.8194397
conversion_datetime: 2025-12-30 02:19:01.227991
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vyepti

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10966 /202402  | Periodic Safety Update EU Single assessment - eptinezumab                                               | 03/10/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| II/0021/G            | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 12/09/2024                          |                                             | SmPC, Annex II, Labelling and PL |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                               |            |            |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| II/0020             | B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol                                          | 12/09/2024 |            | SmPC and PL            |                                   |
| IA/0019             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 16/05/2024 |            | Annex II               |                                   |
| PSUSA/10966 /202308 | Periodic Safety Update EU Single assessment - eptinezumab                                                                                                                                                                                    | 07/03/2024 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0017             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                       | 22/12/2023 | n/a        |                        |                                   |
| X/0011              | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                   | 12/10/2023 | 07/12/2023 | SmPC, Labelling and PL |                                   |
| PSUSA/10966 /202302 | Periodic Safety Update EU Single assessment - eptinezumab                                                                                                                                                                                    | 28/09/2023 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0012   | - Stability of FP - Change in storage for biological medicinal products, when the studies have not been performed in with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                               | 21/09/2023   | 07/12/2023   | SmPC and PL   | B.II.f.1.c conditions stability accordance   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------|
| IB/0015/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                                                                     | 19/09/2023   | n/a          |               | variation                                    |
| IA/0014/G | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 13/07/2023   | n/a          |               |                                              |
| II/0008   | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the                                                                                                                                                                                                                                                                                                                                                                                                         | 20/04/2023   | n/a          |               |                                              |

<div style=\"page-break-after: always\"></div>

|           | change requires an assessment of comparability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| II/0005/G | This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other | 20/04/2023 | n/a | variation |

<div style=\"page-break-after: always\"></div>

| PSUSA/10966 /202208   | Periodic Safety Update EU Single assessment - eptinezumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 16/03/2023   | n/a        |                     | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------------|-------------------------------------|
| IB/0009               | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15/02/2023   | n/a        |                     |                                     |
| IB/0007/G             | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 04/01/2023   | n/a        |                     |                                     |
| IB/0004               | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/11/2022   | 29/06/2023 | SmPC, Labelling and |                                     |

<div style=\"page-break-after: always\"></div>

|                     | tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                |            |            | PL          |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10966 /202202 | Periodic Safety Update EU Single assessment - eptinezumab                                                         | 29/09/2022 | n/a        |             | PRAC Recommendation - maintenance |
| IAIN/0003           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                | 16/08/2022 | n/a        |             |                                   |
| II/0001             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 16/06/2022 | 29/06/2023 | SmPC and PL |                                   |